Needham & Company LLC Reiterates "Buy" Rating for LivaNova (NASDAQ:LIVN)

Needham & Company LLC restated their buy rating on shares of LivaNova (NASDAQ:LIVN - Free Report) in a report issued on Monday morning,Benzinga reports. Needham & Company LLC currently has a $75.00 target price on the stock.

Several other analysts also recently weighed in on LIVN. StockNews.com downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Saturday, November 16th. Baird R W raised LivaNova from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 17th. The Goldman Sachs Group initiated coverage on LivaNova in a report on Friday, October 4th. They issued a "buy" rating and a $65.00 price objective on the stock. Robert W. Baird raised their price target on LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a report on Thursday, October 31st. Finally, Mizuho dropped their price target on LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, LivaNova presently has a consensus rating of "Buy" and an average target price of $69.17.

LivaNova Stock Performance

NASDAQ:LIVN traded up $0.59 during mid-day trading on Monday, reaching $51.91. The company's stock had a trading volume of 210,834 shares, compared to its average volume of 612,755. The firm's fifty day moving average price is $52.13 and its two-hundred day moving average price is $52.45. LivaNova has a 12-month low of $42.75 and a 12-month high of $64.47. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock has a market cap of $2.82 billion, a P/E ratio of 123.64 and a beta of 1.01.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Fifth Third Bancorp raised its holdings in LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company's stock worth $37,000 after purchasing an additional 332 shares in the last quarter. Hexagon Capital Partners LLC raised its stake in LivaNova by 117.8% during the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company's stock valued at $37,000 after purchasing an additional 370 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in shares of LivaNova in the first quarter valued at $84,000. Canada Pension Plan Investment Board bought a new position in shares of LivaNova in the second quarter worth about $88,000. Finally, Acadian Asset Management LLC bought a new position in LivaNova during the 1st quarter worth about $94,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.